Unknown Manufacturer
Nifurtimox is an antiparasitic drug used for the treatment of Chagas disease (Trypanosoma cruzi infection).
Nifurtimox is an antiparasitic drug used for the treatment of Chagas disease (Trypanosoma cruzi infection).
The mechanism of action of nifurtimox has not been fully elucidated, however, is believed to occur by the activation of nitroreductase enzymes that produce reactive metabolites with a series of deleterious effects on Trypanosoma cruzi, the parasite causing Chagas disease. The antiprotozoal actions of nifurtimox occur both intracellularly and extracellularly. Inhibition of parasite dehydrogenase activity is another purported mode of action of nifurtimox that warrants further research.
Nifurtimox is indicated in pediatric patients under 18 weighing at least 2.5 kg. Continued approval of this drug for this indication is dependent upon confirmatory clinical trial results.
1 associated conditions
One entry per invention. Patent families filed in the US, EP, WO and CN offices.
